microRNAs and their therapeutic strategy in phase I and phase II clinical trials

被引:11
|
作者
Ameya, K. P. [1 ]
Kaliaperumal, Kumaravel [2 ]
Sekar, Durairaj [1 ]
机构
[1] Saveetha Univ, Saveetha Dent Coll & Hosp, Saveetha Inst Med & Tech Sci SIMATS, RNA Biol Lab, Chennai 600077, India
[2] Saveetha Univ, Saveetha Dent Coll, Dept Orthodont, Unit Biomat Res, Chennai 600077, Tamil Nadu, India
关键词
clinical trials; diseases; miRNAs; miRNA therapeutics; signaling pathway; CANCER; DELIVERY; BIOMARKERS; PATHWAY; DISEASE; DRUG;
D O I
10.2217/epi-2023-0363
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
miRNAs play a crucial therapeutic role in diseases such as cancer, diabetes and viral infections, with around 1900 identified in the human genome. Some have progressed to clinical trials, and miRNA mimics and miRNA inhibitors are pivotal therapeutic molecules undergoing evaluation. The review delves into various miRNA-associated clinical trials, emphasizing their precision in targeting specific genes, modulating disease pathways and diagnostic potential. This underscores the importance of miRNA therapy, foreseeing innovations in precision medicine techniques for diverse diseases. The future envisions improved delivery systems addressing challenges like immunogenicity and digestion, while a comprehensive miRNA-based omics database could guide the development of tailored antisense miRNAs, further advancing precision medicine strategies.
引用
收藏
页数:14
相关论文
共 50 条
  • [21] Patient motivations surrounding participation in phase I and phase II clinical trials of cancer chemotherapy
    Z A Nurgat
    W Craig
    N C Campbell
    J D Bissett
    J Cassidy
    M C Nicolson
    British Journal of Cancer, 2005, 92 : 1001 - 1005
  • [22] Investigational drug therapies in phase I and phase II clinical trials for alcohol use disorders
    Walker, Leigh C.
    Lawrence, Andrew J.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2018, 27 (08) : 677 - 690
  • [23] Investigational phosphodiesterase inhibitors in phase I and phase II clinical trials for Alzheimer's disease
    Prickaerts, Jos
    Heckman, Pim R. A.
    Blokland, Arjan
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2017, 26 (09) : 1033 - 1048
  • [24] Investigational drugs for the treatment of cancer cachexia: a focus on phase I and phase II clinical trials
    Molfino, Alessio
    Amabile, Maria Ida
    Giorgi, Antonella
    Monti, Massimo
    D'Andrea, Vito
    Muscaritoli, Maurizio
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2019, 28 (08) : 733 - 740
  • [25] Gene therapy of human melanoma Phase I/II clinical trials
    Mackiewicz, A
    Kapciaska, M
    Wiznerowicz, M
    Malicki, J
    Nowak, J
    Murawa, P
    Sibilska, E
    Kowalczyk, D
    Lange, A
    Hawley, RG
    RoseJohn, S
    CANCER GENE THERAPY, 1997, 4 (05) : 336 - 336
  • [26] Efficacy and safety of liposomal anthracyclines in phase I/II clinical trials
    Alberts, DS
    Muggia, FM
    Carmichael, J
    Winer, EP
    Jahanzeb, M
    Venook, AP
    Skubitz, KM
    Rivera, E
    Sparano, JA
    Dibella, NJ
    Stewart, SJ
    Kavanagh, JJ
    Gabizon, AA
    SEMINARS IN ONCOLOGY, 2004, 31 (06) : 53 - 90
  • [27] Novel Statistical Designs for Phase I/II and Phase II Clinical Trials With Dose-Finding Objectives
    Sverdlov, Oleksandr
    Wong, Weng Kee
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2014, 48 (05) : 601 - 612
  • [28] Novel Statistical Designs for Phase I/II and Phase II Clinical Trials With Dose-Finding Objectives
    Oleksandr Sverdlov
    Weng Kee Wong
    Therapeutic Innovation & Regulatory Science, 2014, 48 : 601 - 612
  • [29] RANDOMIZED PHASE II CLINICAL TRIALS
    Jung, Sin-Ho
    Sargent, Daniel J.
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2014, 24 (04) : 802 - 816
  • [30] Phase I Cancer Clinical Trials
    J A Ledermann
    British Journal of Cancer, 2007, 96 (8) : 1311 - 1311